Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101 View HTML
Toggle Summary Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA View HTML
Toggle Summary Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates View HTML
Toggle Summary Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
Management to host conference call
View HTML
Toggle Summary Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors View HTML
Toggle Summary Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates View HTML
Toggle Summary Minerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017 View HTML
Toggle Summary Minerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017 View HTML
Toggle Summary Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia View HTML
Toggle Summary Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function View HTML